jff super ace ultimate
By Greg Otto December 16, 2024 Minnesota-based Arctic Wolf, a cybersecurity operations firm, announced an agreement Monday to acquire BlackBerry’s Cylance business for $160 million, a stark drop from the $1.4 billion BlackBerry initially paid to acquire the startup in 2018. Arctic Wolf is integrating Cylance’s AI-powered endpoint security technology into its platform to broaden its security solutions. With this acquisition, Arctic Wolf plans to bolster its presence in the competitive cybersecurity market, leveraging Cylance’s technology. It marks Arctic Wolf’s sixth acquisition to date, enhancing its portfolio with previous acquisitions such as RootSecure and Tetra Defense. The sale includes a cash payment and approximately 5.5 million common shares of Arctic Wolf, with BlackBerry set to receive around $80 million at closing and the remainder following in fiscal 2025. The deal is expected to be finalized in BlackBerry’s fiscal Q4. John Giamatteo, CEO of BlackBerry, highlighted the sale’s benefits for all stakeholders involved, ensuring continuity for Cylance’s clients. “Our customers will realize the benefits of continuity of service and the expertise that Arctic Wolf provides,” he said in a statement, noting that BlackBerry will remain involved in the sector as a reseller and shareholder post-transaction. Cylance, founded in 2012 and acquired by BlackBerry in 2018, initially anticipated a strengthened position in the cybersecurity space. Prior to the acquisition, the tool was instrumental in discovering the malware responsible for the historic breach at the Office of Personnel Management. However, market shifts toward threat detection and response — capabilities that Cylance lacked — dampened its market hold. Nick Schneider, Arctic Wolf’s CEO, expressed the imperative need for integrated security operations, identifying weakness in isolated point solutions. “Security has an operations and effectiveness problem and endpoint solutions alone have failed to live up to the outcomes they have promised for years,” Schneider stated , emphasizing the need for a unified platform that effectively minimizes risk and enhances resilience. The planned integration of Cylance’s AI capabilities into Arctic Wolf’s open-XDR Aurora platform is set to advance endpoint security deliverables and harness automated intelligence to preemptively counteract cybersecurity threats.U.S. Sen. Joe Manchin bids farewell to Capitol Hill with criticism of Democrats and calls for a third party
TETRA TECHNOLOGIES, INC. INTRODUCES TETRA OASIS TOTAL DESALINATION SOLUTION (TETRA OASIS TDS) AND RESULTS FROM PERMIAN BASIN BENEFICIAL RE-USE PILOTWILMINGTON, N.C. (AP) — Dior Conners led Appalachian State with 19 points and Myles Tate made a jumper from the free-throw line with 25.1 seconds left as the Mountaineers knocked off Sam Houston 66-63 on Wednesday night. Conners shot 4 of 9 from the field, including 2 for 5 from 3-point range, and went 9 for 10 from the line for the Mountaineers (4-2). Tate scored 17 points, going 6 of 14 from the floor, including 3 for 6 from 3-point range, and 2 for 4 from the line. Jackson Threadgill had 11 points and shot 4 for 11, including 1 for 3 from beyond the arc. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
In France, start of construction of three photovoltaic projects Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energy, launches construction of three new solar power plants in the south of France with a total capacity of 25.1 megawatts The first project involves the construction of a photovoltaic park with a total output of 10.7 megawatts. The project is located on a 15-hectare agricultural wasteland. The choice of a specific technology for the structures supporting the solar panels with trackers 1 and the implementation of an appropriate irrigation system will enable farming activities to resume. The other two projects, with capacities of 8.2 megawatts and 6.2 megawatts respectively, are solar farms with fixed structures. In total, the production of the three projects represents the annual electricity consumption of more than 18,000 inhabitants and will prevent the emission of 7,500 tonnes of CO 2 . “ With a capacity of 461 megawatts in operation and under construction, Voltalia is a major player in renewable energy in mainland France and French Guiana. In addition, Voltalia is developing a pipeline of more than two gigawatts of future projects in the country” , said Sébastien Clerc, Chief Executive Officer of Voltalia. Next on the agenda: Q4 2024 turnover, January 29, 2025 (after market close) 1 Mobile structures that rotate the solar panels to follow the sun's path from morning to night Attachment In France, start of construction of three photovoltaic projects
United States of America has the world's oldest democracy but the country is yet to get a female President. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping Former President Bill Clinton and Sen. Lindsey Graham, R-S.C., don't agree on much. Yet, recently the ideological adversaries found some common ground on a political question that has quietly endured over nearly two decades. Yes, a woman can win the White House, they agree. But she's probably going to be conservative, NYT News Service reported. "Are there women out there, governors, Republican, Democrat, that can be the next president of the United States? Absolutely," Graham said in an interview on Capitol Hill this month. "If you have a Republican female nominee, they would have a good shot of being the first woman president." A few days earlier and several hundred miles north, Clinton -- whose wife tried and failed twice to win the White House -- made a similar argument, as per a report on NYT News Service . Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program "Ideologically, the people who are most likely to be against women are most likely to be conservative, so when people agree with you, it's easier to be for them," he said in an appearance at the DealBook Summit hosted by The New York Times. "But I think a woman can be elected president. I do." Their similar predictions are the latest in a conversation that has frustrated and foiled two generations of female candidates. For Democrats still scarred by Hillary Clinton 's loss to Donald Trump in 2016, Vice President Kamala Harris ' defeat at the hands of the same man in November has only deepened anxieties over gender bias and prompted a fresh round of debate over the electability of women to the nation's highest office. For decades, advocates for female political leaders argued that if more women ran for president, their presence in American politics would become normalized and one would eventually win the White House. Since Clinton's first attempt to break what she called "that highest, hardest glass ceiling" in 2008, nine other women have vied for a major party's nomination. Those candidates have been conservative and liberal, racially diverse, and from big cities, small towns and across the country. Some campaigned on an economic message, others focused on social issues. Only two -- Clinton and Harris, both Democrats -- captured their party's nomination. As they process the second defeat of a female nominee, Democrats are divided over the question of how much Harris' gender actually contributed to her loss, making it hard to divine what exactly that could mean for their party in 2028. Two weeks before Election Day, Harris openly dismissed concerns that sexism could hurt her chances, saying in an interview with NBC News that the country was "absolutely" ready to elect a female president. FAQs Q1. Who is President of USA? A1. President of USA is Joe Biden. Q2. What is current designation of Donald Trump? A2. Donald Trump's current designation is US President-elect. (You can now subscribe to our Economic Times WhatsApp channel )
TORONTO — (“ ” or the “ ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has filed a preliminary prospectus supplement (the “ ”) and intends to file a subsequent prospectus supplement (the “ ”) to its short form base shelf prospectus dated April 7, 2024 (the “ ”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a commercially reasonable best efforts offering (the “ ”) of common shares of the Company (“ ”). The Offering is expected to be completed on a commercially reasonable best efforts agency basis pursuant to an agency agreement (the “ “) to be entered into between the Company and Bloom Burton Securities Inc. (the “ “), as lead agent and a syndicate of agents (collectively, together with the lead agent, the “ “). The number of Securities to be distributed, the price of each Security and the size of the Offering will be determined by negotiation between the Company and the Lead Agent in the context of the market with final terms to be determined at the time of pricing. It is anticipated the Offering will also include the optional issuance of pre-funded common share purchase warrants (“ ”) of the Company in lieu of Common Shares at the discretion of purchasers of the Offering. Each Pre-Funded Warrant issued in lieu of a Common Share at the election of any purchaser (together with the Common Shares, the “ ”) entitles the holder thereof to acquire one common share (a “ ”) at a nominal exercise price. The Pre-Funded Warrants do not expire. The Company intends to use the net proceeds from the Offering to advance its Phase 2 clinical development of SAT-3247, as well as working capital needs and other general corporate purposes, as set out in the Preliminary Prospectus Supplement. The Offering is expected to close on or about December 20, 2024, or such other date as may be mutually agreed to by the Company and the Lead Agent (the “ “). The Offering is subject to the Company and the Agents entering into a definitive agency agreement, and subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the Toronto Stock Exchange (“ ”). In addition, the Securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws. For further details with respect to the Offering, please see the Preliminary Prospectus Supplement, a copy of which is available on SEDAR+ at . Access to the Base Shelf Prospectus, the Prospectus Supplement, and any amendments to the documents will be provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Base Shelf Prospectus is, and the Prospectus Supplement will be (within two business days of the date hereof), accessible on SEDAR+ at . Alternatively, an electronic or paper copy of the Base Shelf Prospectus, the Prospectus Supplement (when filed), and any amendment to the documents may be obtained without charge, from the Lead Agent by email at ,by telephone at [416-640-7585] or by providing the contact with an email address or address, as applicable. The Base Shelf Prospectus and Prospectus Supplement contain important, detailed information about the Company and the proposed Offering. Prospective investors should read the Base Shelf Prospectus and Prospectus Supplement (when filed) before making an investment decision. This press release is not an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “ ”), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the “United States” or “U.S. Persons” (as such terms are defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company’s securities to, or for the account or benefit of, persons in the United States or U.S. Persons. Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support its discovery that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate, SAT-3247, is currently in clinical development as a potential disease-modifying treatment for DMD. Additionally, Satellos is leveraging its breakthrough research and proprietary discovery platform MyoReGenXTM, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit . This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements with respect to the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; inclusion of additional agents; fees anticipated to be paid to the Agent and terms thereof; regulatory and exchange approvals, including the listing of the common shares offered pursuant to the Offering on the TSX; general benefits of modulating stem cell polarity; its prospective impact on Duchenne patients and muscle regeneration generally; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the Preliminary Prospectus Supplement and the Annual Information Form dated March 26, 2024 (both of which are on the Company’s profile at ). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Liz Williams, CFO, Jessica Yingling, Ph.D., , +1.858.344.8091
Aston Villa’s disallowed goal would have counted in England – Unai Emery
Stock market today: Nasdaq hits a record as Wall Street drifts ahead of Federal Reserve's meetingJimmy Carter, the 39th US president, has died at 100Buccaneers looking to beat NFC South-rival Panthers and bolster hopes for a playoff berth
